About
Explore Cell Therapies

About Cell Therapies

Our Facility

View our Services

Partnerships and Collaborations

Careers at Cell Therapies

Contact us

Since 2003, Cell Therapies has manufactured cell therapies, ex vivo gene therapies, and regenerative medicine products under GMP standards to meet global regulatory requirements.

Learn about Cell Therapies
Services
Explore Services

Contract Manufacturing

Technology Transfer

Process Development

Analytical Testing and Development

Quality as a Service

Consulting and Advisory

Clinical Trial Support

Cryopreservation & Logistics

Digitalization & Automation

With over two decades of experience in GMP manufacturing of cell-based products, Cell Therapies is a trusted partner in transforming promising research into scalable, compliant, and commercially viable therapies.

Learn about Our Services
Facility
Careers
Explore Careers

Careers at Cell Therapies

View Current Opportunities

Upload your Resume

We are always on the lookout for curious minds, problem-solvers, and biotech enthusiasts to join our team. If you have a background in GMP manufacturing, QC, QA, engineering, or cell and gene therapy development, we would love to hear from you.

Find out about a career at Cell Therapies
News and Resources
Explore News and Resources

All News and Resources

News

Resources

Filter
All News
Resources

Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region
Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region
Read More

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration
Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration
Read More

CTPL sign MoU with Xellera to Fast-Track CGT Access across APAC
CTPL sign MoU with Xellera to Fast-Track CGT Access across APAC
Read More

Read the latest from Cell Therapies
Contact

News

Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region

October 1, 2025 — Cell Therapies Pty Ltd. (“Cell Therapies”) and Teijin Limited announced today…

Josh DowningSeptember 30, 2025

News

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration

Cell Therapies Pty Ltd (Cell Therapies) and Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) have…

Cell TherapiesJuly 16, 2025

News

CTPL sign MoU with Xellera to Fast-Track CGT Access across APAC

Cell Therapies and Xellera Therapeutics Enter into a Strategic Partnership to Fast-Track Access to Cell…

Josh DowningApril 1, 2025

News

Cell Therapies to partner with Chimeric Therapeutics Ltd

Cell Therapies are pleased to announce that they are partnering with Chimeric Therapeutics to…

Josh DowningAugust 9, 2024

Resources

Technology Transfers for CGT products: Understanding what is needed for success

Transferring a cell and gene therapy (CGT) product from development to manufacturing involves a detailed…

Cell TherapiesJune 20, 2024

News

CTPL to be AdAlta’s preferred manufacturer of immunotherapies

Cell Therapies Pty Ltd to be preferred manufacturer of cellular immunotherapies Establishes key partnership to…

Cell TherapiesMay 12, 2024

Resources

Quality Assurance: The Importance of Robust Investigations

Quality Assurance: The Importance of Robust Investigations Quality Assurance (QA) is a broad process that…

Cell TherapiesApril 22, 2024

Resources

Ensuring Every Batch is a Success: Validation and Qualification

Ensuring Every Batch is a Success: Validation and Qualification in Cell and Gene Therapy Manufacturing…

Cell TherapiesMarch 10, 2024

Resources

Translating research discoveries to commercialised cell and gene therapy products; asking the right questions as an academic.

When translating research discoveries in the cell and gene therapy sector, numerous considerations must be…

Cell TherapiesNovember 28, 2023

News

Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials

Cell Therapies Pty Ltd is partnering with Arovella Therapeutics (ASX: ALA) to develop the manufacturing…

Cell TherapiesNovember 8, 2023

Resources

From Concept to Commercialisation: Why the selection of an organisation for a cell and gene therapies can impact your patient outcomes and competitive advantage

The development pipeline of cell and gene therapies faces numerous obstacles while striving for the…

Cell TherapiesAugust 14, 2023

News

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Bev Menner as the company’s new Chief Executive Officer.

Cell Therapies Pty Ltd, a leading provider of cell and gene therapy products in the…

Cell TherapiesJuly 26, 2023

Filter

Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration

CTPL sign MoU with Xellera to Fast-Track CGT Access across APAC

News and Resources

The latest news and insights from Cell Therapies

Cell Therapies and Teijin Announce Strategic Collaboration to Expand Access to Advanced Cell and Gene Therapies in Japan and the Asia Pacific Region

Cell Therapies and Viral Vector Manufacturing Facility (VVMF) enters strategic collaboration

CTPL sign MoU with Xellera to Fast-Track CGT Access across APAC

Cell Therapies to partner with Chimeric Therapeutics Ltd

Technology Transfers for CGT products: Understanding what is needed for success

CTPL to be AdAlta’s preferred manufacturer of immunotherapies

Quality Assurance: The Importance of Robust Investigations

Ensuring Every Batch is a Success: Validation and Qualification

Translating research discoveries to commercialised cell and gene therapy products; asking the right questions as an academic.

Arovella Therapeutics partners with Cell Therapies to develop its ALA-101 manufacturing process for cancer clinical trials

From Concept to Commercialisation: Why the selection of an organisation for a cell and gene therapies can impact your patient outcomes and competitive advantage

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Bev Menner as the company’s new Chief Executive Officer.

Unrivalled experience and service from a global leader in cell and gene therapy manufacturing

Services

Helpful Links

Corporate